BioLine RX Ltd expected to post a loss of 5 cents a share - Earnings Preview

Reuters11-22
BioLine RX Ltd <blrx.oq> expected to post a loss of 5 cents a share - Earnings Preview </blrx.oq>
  • BioLine RX Ltd BLRX.OQ, BLRX.O is expected to show a rise in quarterly revenue when it reports results on November 25 for the period ending September 30 2024

  • The Modiin Israel-based company is expected to report revenue of $5.29 million, according to the mean estimate from 3 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for BioLine RX Ltd is for a loss of 5 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for BioLine RX Ltd is $6.50​, above​ its last closing price of $0.32. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Jun. 30 2024

-0.14

-0.14

0.00

Beat

100

Mar. 31 2024

-0.29

-0.29

-0.01

Beat

96.6

Dec. 31 2023

-0.22

-0.16

-0.15

Beat

9.1​

Sep. 30 2023

-0.26

-0.30

Missed

-15.4

​​Jun. 30 2023

-0.11

-0.13

-0.30

Missed

-130.8

Mar. 31 2023

-0.18

-0.17

-0.15

Beat

11.8​

Dec. 31 2022

-0.09

-0.12

-0.15

Missed

-20

Sep. 30 2022

-0.15

-0.15

Met

0

This summary was machine generated November 22 at 13:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment